EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Strategic Alliances and Business Partnerships Across the U.S. Pharmaceutical Industry
US pharma partnerships are formal agreements in which two or more companies share the cost risk technology or market access involved in developing and selling a drug The most common forms are licensing deals codevelopment agreements cocommercialization arrangements and joint ventures Companies enter them because bringing a single drug
-
Techno Trends
Glycomine’s GLM101 Receives FDA Breakthrough Therapy Designation
Glycomine has received Breakthrough Therapy designation from the US Food and Drug Administration FDA for GLM an investigational treatment for phosphomannomutase congenital disorder of glycosylation PMMCDG a rare multisystem disorder with no approved therapies
-
Projects
Hovione Opens US$100 milllion East Windsor Pharma Manufacturing Expansion
Pharmaceutical CDMO Hovione has opened a new squarefoot facility at its East Windsor campus in New Jersey completing its current US million US investment programme The expansion doubles Hoviones US spraydrying capacity and strengthens its pharmaceutical development
-
Research Insights
Synthesis and evaluation of haemocompatible, antioxidant, and antibacterial properties, and acute oral toxicity of a methacrylic acid mediated glucoxylan for wound healing applications
Herein a copolymeric hydrogel comprising a naturally occurring swellable biopolymer ie glucoxylan a major polysaccharide of chia seed mucilage CM and methacrylic acid MA was synthesized through free
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Future of Pharma IT Infrastructure: Building Agile, Secure, and Data-Driven Enterprises
Lakshmi
American pharmaceutical companies are discovering that IT infrastructure sets the ceiling on everything else: how fast a product scales, how quickly quality issues surface, how far AI can be trusted....
-
2
One Health and Antimicrobial Resistance
Ramendra Pati Pandey
Gajala Deethamvali Ghouse Peer
Carlos R Prudencio
Antonio Charlys da Costa
Elcio Leal
Chung-Ming Chang
It is for the most part recognized that we share many elements with other creature species, which are surely pertinent when the ideas of health and disease are talked about. The term 'One Health&#...
-
3
Winning the Biosimilars Market: Strategic Imperatives for Sustainable Growth
Lakshmi
The U.S. biosimilars market is entering a period of intense price competition, where commercial strategy—not scientific differentiation—determines success. Using the adalimumab market as a...
-
4
The Procedure of Pharmaceutical Development
Xiaoya Zhang
Pharmaceutical development is the identification and evaluation of cycles needs to change over a functioning drug fixing into a medication item reasonable for its expected reason. In the beginning pha...
-
5
Modern Mental Health Medications: A Guide to Antidepressants, Anxiety Drugs, and New Treatments
No Author
Mental health is no longer a hidden issue—it's a vital focus in healthcare worldwide. With millions seeking effective treatment options, the landscape of mental health medications has expand...
press releasesRead more...
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
Genentech a member of the Roche Group SIX RO ROP OTCQX RHHBY announced today that the US Food and Drug Administration FDA has accepted the companys New Drug Application NDA
MedImpact Launches Claria™, a Distinctively New Approach to Delivering Pharmac Benefits
MedImpact the nations largest independent pharmacy benefit and health solutions company today introduced Claria an industryfirst approach that transforms PBM economics by giving plan
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
Codexis Inc NASDAQ CDXS a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing today announced an agreement with a pioneering siRNA drug innovator
Lifecore Biomedical to be Acquired by Webster Equity Partners
Lifecore Biomedical Inc Nasdaq LFCR today announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to million assuming full achievement
Events Read more...
28 - 02
Sep 2026Discovery on Target 2026
Boston, MA, USA
05 - 06
Oct 2026ISPSAI France 2026
Paris, France
05 - 08
Oct 202616th World CB & CDx Summit 2026
Boston, MA, USA
12 - 14
Oct 2026Pharmaceutics 2026
Village Hotel Changi, Singapor...
12 - 13
Oct 20262nd International Conference on Drug Discovery
Village Hotel Changi, Singapor...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
LATEST NEWSRead more...
AbbVie Partners with Valkai to Expand AI Use in Clinical Development
AbbVie has partnered with Valkai a life sciences artificial intelligence AI platform to expand the use of AI across selected areas of clinical development
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to million subject to the achievement of certain performance milestones
Meitheal Pharmaceuticals Announces FDA Approval of High-Concentration Formulation of YUSIMRY®, a Biosimilar to Humira®
Meitheal Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved a highconcentration formulation of YUSIMRY adalimumabaqvh an interchangeable biosimilar to Humira
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Merck known as MSD outside of the United States and Canada and SciBrunch Therapeutics Co Ltd SciBrunch today announced that they have entered into an exclusive global license agreement for SPR an investigational preclinical oral KRAS GD ON inhibitor
FDA Grants Breakthrough Therapy Designation to Glycomine’s GLM101 for PMM2-CDG
The US Food and Drug Administration FDA has granted Breakthrough Therapy designation to Glycomines investigational GLM for the treatment of phosphomannomutase congenital disorder of glycosylation PMMCDG
Elevar Therapeutics Announces FDA Approval of Lyrfigtu for FGFR2-Altered Cholangiocarcinoma
Elevar Therapeutics has announced that the US Food and Drug Administration FDA has approved LYRFIGTU lirafugratinib as a treatment option for patients with cholangiocarcinoma CCA with an FGFR fusion or other rearrangement
